摘要
5例肺血栓栓塞症住院患者,男3例,女2例,年龄46～67岁,给予那屈肝素钙0.7～0.8mL(7175～8200IU)/12h或达肝素钠0.2mL(5000IU)/12h皮下注射抗凝治疗。用药后3～8d均出现肝功能异常,AST48～157U/L,ALT92～288U/L、γ-GT52～248U/L。停药并给予保肝治疗3～5d后,患者肝酶水平均好转。
Five in-patients with pulmonary thromboembolism,3 males and 2 females aged 46-67 years,received anticoagulant therapy with SC nadroparin calcium 0.7-0.8 mL（7175-8200 IU）12-hourly or dalteparin sodium 0.2 mL（5000 IU）12-hourly.Three to eight days after the treatment,all of them developed hepatic dysfunction.Laboratory tests showed the following results of liver enzymes：AST 48-157 U/L,ALT 92-288 U/L,and γ-GT 52-248 U/L.The medicines were discontinued and the patients were treated with liver protective therapy.Three to five days later,their liver enzyme levels improved.
出处
《药物不良反应杂志》
2010年第5期346-348,共3页
Adverse Drug Reactions Journal
关键词
肺血栓栓塞症
低分子肝素
不良反应
肝功能异常
pulmonary thromboembolism
low molecular weight heparin
adverse reactions
hepatic dysfunction
